Alexion Pharmaceuticals Aktie News & Pressemeldungen

Noticias de Eulerpool Alexion Pharmaceuticals

24/10/2024, 22:53:44

Monopar Therapeutics sichert sich Exklusivlizenz von Alexion für vielversprechendes Wilson-Therapeutikum

25/10/2024, 18:03:04

Monopar Therapeutics sichert sich globale Lizenz für ALXN-1840

30/10/2024, 10:55:53

NurExone zeigt Innovationskraft in der Exosomen-Forschung

13/11/2024, 15:49:02

Revolutionäre Fortschritte in der Neurowissenschaft: Voyager Therapeutics setzt auf Tau-Targeting

13/11/2024, 16:18:50

Durchbruch in der Behandlung von Neurofibromatose Typ 1: AstraZeneca und Merck zeigen herausragende Studienergebnisse

Alexion Pharmaceuticals Noticias de Acciones

Alexion Pharmaceuticals es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Alexion Pharmaceuticals.

22 de julio ·
Thefly.com
Three new option listings and four option delistings on July 22nd
20 de julio ·
Nasdaq
After Hours Most Active for Jul 20, 2021 : ALXN, MRNA, HON, WORK, AAPL, PKW, ZNGA, EOG, AMC, BAC, CLF, GE
20 de julio ·
GuruFocus
Samson Rock Capital LLP Buys Proofpoint Inc, Alexion Pharmaceuticals Inc, Nuance Communications Inc, Sells , RealPage Inc,
19 de julio ·
Alliance News
NEW YORK MARKET CLOSE: Deep falls as Delta dampens virus rebound hope
16 de julio ·
MarketWatch
Moderna Shares Climb 8.7% on Addition to S&P 500 Stock Index
16 de julio ·
Nasdaq
Why Moderna Stock Just Jumped 10%
16 de julio ·
Investing.com
Wall Street Opens Higher; Moderna Shines After S&P 500 Inclusion; Dow up 30 Pts By Investing.com
16 de julio ·
Alliance News
TOP NEWS: Moderna shares jump as set to join S&P 500 index
15 de julio ·
Yahoo
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
15 de julio ·
CNBC
Stock futures slip as Wall Street wraps up first week of second-quarter earnings

Alexion Pharmaceuticals Noticias de la acción

Alexion Pharmaceuticals publica regularmente en la página web de la empresa noticias relevantes para los inversores.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Suscripción por 2 € / mes

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan